21.11.2022 13:26:44

Teva Appoints Richard Francis As CEO On Retirement Of Kåre Schultz

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Monday said it has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023, following retirement of current CEO Kåre Schultz.

Schultz will retire from his current position, effective December 31, 2022, the company said.

Francis with more than two and a half decades of experience as a pharmaceutical executive, is currently serving as CEO of Syncona's portfolio companies, AAV gene therapy company, Purespring Therapeutics, and Forcefield Therapeutics.

Analysen zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel